Literature DB >> 25917761

Clinical characteristics and treatment outcomes of primary and recurrent malignancy involving the salivary glands in children.

Sajid S Qureshi1, Monica Bhagat1, Nitin Singhal1, Nitin Tathe1, Seema Kembhavi2, Siddharth Laskar3, Mukta Ramadwar4, Prabha Yadav5.   

Abstract

BACKGROUND: Malignant salivary gland neoplasms are rare in children. The purpose of this study was to present our experience in the treatment of primary and recurrent salivary gland neoplasm and contribute to the fractional available data.
METHODS: All patients <18 years, treated between June 2005 and April 2014 were included in this study.
RESULTS: The parotid gland was the most common site for both primary (n = 18) and recurrent (n = 6) tumors and mucoepidermoid carcinoma, low or intermediate grade, main histological type. Surgical excision was performed in all patients, of which 13 patients received radiotherapy. Lymph node metastasis was present in 3 patients with primary tumor, which were assessed accurately on frozen section examination. Local recurrence occurred in 1 patient with primary tumor and all patients are alive.
CONCLUSION: Surgery is the prime modality of treatment for malignant salivary gland neoplasm and is associated with excellent outcomes. The role of lymph node sampling and frozen section examination needs further evaluation in identifying lymph node metastasis.
© 2015 Wiley Periodicals, Inc. Head Neck 38: 852-856, 2016. © 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  children; malignant; mucoepidermoid carcinoma; salivary gland neoplasm; surgery

Mesh:

Year:  2015        PMID: 25917761     DOI: 10.1002/hed.24114

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  1 in total

1.  Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio in Pediatric Parotid Cancer.

Authors:  Dongjie Seng; Qigen Fang; Peng Li; Fei Liu; Shanting Liu
Journal:  Front Pediatr       Date:  2019-05-24       Impact factor: 3.418

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.